Giuseppe Caruso, Gynecology Oncology Specialist at European Institute of Oncology, shared a post on LinkedIn:
“This morning I met a patient diagnosed with a very rare condition: adult type ovarian granulosa cell tumor (AGCT).
She asked a simple yet powerful question: “Is anything moving forward in research for rare diseases like mine?”
By chance, over breakfast, I had just come across this recent paper offering a nice comprehensive overview of the latest developments in this field, including:
- Dual checkpoint inhibitor immunotherapy
- CDK4/6 inhibitor + aromatase inhibitor
- TGF-beta pathway inhibitor
A timely reminder that even in rare cancers – where evidence is limited and progress can feel slow – research is advancing.
For clinicians, staying updated is not just an academic exercise – it directly impacts the conversations we have with our patients.
And sometimes, it allows us to give a more hopeful answer.
Title: New therapeutic strategies for relapsed adult type ovarian granulosa cell tumors: From discovery to clinical progress.
Authors: Harriet Rothschild, R. Tyler Hillman.
Other articles featuring Giuseppe Caruso on OncoDaily.